VIP means vasoactive intestinal peptide. Aviptadil is a synthetic form studied in clinical settings. A VIP label alone does not establish that an item matches the formulation used in a trial.
What the research shows
The 2023 TESICO trial in COVID-19 respiratory failure found no significant clinical-outcome improvement over placebo. A 2025 inhaled-aviptadil trial in 80 patients reported shorter hospitalization. Their formulations and outcomes differ, so they cannot support one blanket claim for all VIP products. [1] [2]
Distinguishing substances and products
Distinguish the substance name, aviptadil formulation and specific product documentation. Lung-disease research does not establish general performance or wellness benefits.
Reading a specific brand’s label
Start with the exact substance and product name, then match the label to the manufacturer’s documents. This article does not establish Thai registration or current availability for an unspecified product.
Frequently asked questions
Does every VIP item match aviptadil studied in trials?
No. Formulation, presentation and manufacturer documentation must match.
Can one formulation validate another?
Not automatically; the cited trials used different formulations and populations.
What information helps identify a specific product?
The brand, product name, full label and matching manufacturer documents. Evidence about the substance alone does not establish a product’s identity, registration or quality.
Related information
For general questions about names or label details, contact LINE: @musclestationth
Sources and review date
Sources checked: 11 September 2026. This page explains selected primary sources; it is not a systematic review of every study.